Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases.

Lo Furno D., Mannino G., Giuffrida R.

Clinical Trial on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in J Cell Physiol (2017) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Cell Physiol (2017)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
28926091
DOI
10.1002/jcp.26192

Abstract (original English)

Mesenchymal stem cells (MSCs) can differentiate into not only cells of mesodermal lineages, but also into endodermal and ectodermal derived elements, including neurons and glial cells. For this reason, MSCs have been extensively investigated to develop cell-based therapeutic strategies, especially in pathologies whose pharmacological treatments give poor results, if any. As in the case of irreversible neurological disorders characterized by progressive neuronal death, in which behavioral and cognitive functions of patients inexorably decline as the disease progresses. In this review, we focus on the possible functional role exerted by MSCs in the treatment of some disabling neurodegenerative disorders such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, and Parkinson's Disease. Investigations have been mainly performed in vitro and in animal models by using MSCs generally originated from umbilical cord, bone marrow, or adipose tissue. Positive results obtained have prompted several clinical trials, the number of which is progressively increasing worldwide. To date, many of them have been primarily addressed to verify the safety of the procedures but some improvements have already been reported, fortunately. Although the exact mechanisms of MSC-induced beneficial activities are not entirely defined, they include neurogenesis and angiogenesis stimulat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Alzheimer DiseaseAmyotrophic Lateral SclerosisCell- and Tissue-Based TherapyHumansHuntington DiseaseMesenchymal Stem Cell TransplantationMesenchymal Stem CellsNeurodegenerative DiseasesNeurogenesisNeurons

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research